News

GSK acquires Cellzome 100%
Enlarge image

BusinessUKGermany

GSK acquires Cellzome 100%

16.05.2012 - Britain's largest drugmaker GlaxoSmithKline will pay about €75m in cash to acquire Cellzome AG completely.

London/Heidelberg/Cambridge – The pharma already owns about 20% of all outstanding shares. The privately owned biotech with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK's R&D organisation. GSK knows its acquisition target quite well, as both partners have maintained a research cooperation for four years.

"The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterise drug targets and provides the opportunity to further enhance GSK's ability to bring medicines to patients in a more effective manner," said John Baldoni, senior vice president, Platform & Technology Science, at GSK.

Cellzome's proteomics technologies can be used throughout drug discovery from screening to selectivity profiling of compounds in different cells and also in patient samples. The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.

However, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which "would hold the rights to certain of Cellzome's assets and activities that GSK does not wish to progress".

http://www.european-biotechnology-news.com/news/news/2012-02/gsk-acquires-cellzome-100.html

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%
  • ADDEX3.32 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%

TOP

  • SANTHERA94.75 CHF47.8%
  • FORMYCON8.30 EUR19.9%
  • EPIGENOMICS3.61 EUR14.6%

FLOP

  • EVOTEC3.12 EUR-16.8%
  • MEDIGENE3.98 EUR-15.7%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA94.75 CHF2524.7%
  • CO.DON2.71 EUR218.8%
  • PAION2.71 EUR155.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • 4SC1.16 EUR-40.5%
  • MERCK KGAA68.05 EUR-38.7%

No liability assumed, Date: 14.09.2014